Lung Ambition Alliance reveals plans to double lung cancer survival
Category: #health  By Paroma Bhattacharya  Date: 2019-09-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Lung Ambition Alliance reveals plans to double lung cancer survival
  • New program will be launched to help local initiatives run by patient organizations that contain the capability to further transform patient care.
     
  • The Lung Ambition Alliance has built an interactive booth where applicants will understand integrated quality care in lung cancer is.

The four members of Lung Ambition Alliance, Guardant Health, AstraZeneca, International Association for the Study of Lung Cancer (IASLC) and the Global Lung Cancer Coalition (GLCC) reportedly unveiled several novel initiatives to support their aim of increasing 5-year survival before 2025 at the IASLC World Conference on Lung Cancer.

President at the IASLC, Giorgio Scagliotti stated that the association has made great progress in a mere two months after the announcement of founding the Lung Ambition Alliance. New initiatives of Alliance, such as those in Lung Cancer Care (ILC2), exemplify association’s shared goal to work with the global community and promote ambitious in-country solutions which potentially would enhance lung cancer patient survival rates and also transform patient care.

ILC2 program is appealing enrolled patient organizations that focus on lung cancer, across the globe, to submit the proposals that have the capability to enhance survival into their home countries and transform patient care.

The program is created in identification of the high variation in the management of lung cancer across the globe, and very limited local obstacles to quality care that should be considered while developing solutions convenient to patients to address them.

The Lung Ambition Alliance has built an interactive booth where participants will understand integrated quality care in lung cancer is, while getting access to important resources of quality care along the way. Moreover, participants will also get a chance to provide feedback on this experience with this patient journey.

The Lung Ambition Alliance would officially accept grant proposals in November 2019 and would examine and then select those proposals which have fulfilled the funding criteria.

 

Source credit: https://www.globenewswire.com/news-release/2019/09/07/1912428/0/en/Lung-Ambition-Alliance-unveils-new-initiatives-to-address-lung-cancer-survival-at-the-World-Conference-on-Lung-Cancer.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...